WAT

Waters Corporation (WATERS CORP) - 10-Q Summary

Business Context and Reporting Period

This filing covers the quarterly period ended April 2, 2005. Waters Corporation designs, manufactures, and services analytical instrument systems, including liquid chromatography (LC), mass spectrometry (MS), and thermal analysis instruments. The company operates through two primary divisions: the Waters Division and the TA Instruments Division. The company also provides laboratory informatics software following recent acquisitions.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 5% year-over-year, driven by a 3% increase in product sales and an 11% increase in service sales. Currency translation positively impacted sales growth by 2%.
• Profitability: Operating income rose 14% to $57.9 million. This improvement is largely due to the absence of a $7.8 million litigation provision and $0.1 million in restructuring charges that impacted the prior year's quarter.
• Expense Trends: Selling and administrative expenses increased 13% to $80.6 million, attributed to currency effects, Sarbanes-Oxley compliance costs, merit increases, and new facility expenses. R&D expenses rose 4% to $16.7 million.
• Debt and Liquidity: Total borrowings increased to $585.9 million, primarily to fund an aggressive stock repurchase program. Despite higher debt, cash and cash equivalents grew by $47.8 million during the quarter.
• Segment Performance: TA Division sales grew 16%, while Waters Division LC sales grew 2% and MS sales grew 5%. Europe experienced a 5% sales decline excluding currency effects, attributed to softness in pharmaceutical spending.

Guidance, Outlook, and Risks

• Outlook: Management expects strong performance in industrial, university, and government markets to continue throughout 2005. TA sales growth is expected to remain robust, particularly in Asia and Japan.
• Stock Repurchases: The company continues a $500 million share repurchase program authorized in October 2004. As of April 2, 2005, $204.8 million had been utilized, with $295.2 million remaining available.
• Accounting Changes: The company anticipates a material impact on results of operations upon the adoption of SFAS 123(R) regarding share-based payments, effective for the first annual period beginning after June 15, 2005.
• Tax Legislation: The American Jobs Creation Act of 2004 (AJCA) offers a temporary incentive to repatriate foreign earnings. The company has not yet decided whether to repatriate up to $500 million, which could increase the income tax provision by $25.0 million to $32.0 million.
• Litigation Risks: Ongoing patent litigation with Hewlett-Packard (HP) remains a contingency. While a UK court ruled in the company's favor in December 2004, HP has appealed. A damages trial is rescheduled for December 2005. The company maintains a $4.0 million accrual for this matter.

Investor Verification Checklist

• Pharma Spending: Verify the extent of the "softness" in large pharmaceutical customer spending and its potential duration, given the 5% decline in European sales.
• Stock Repurchase Funding: Confirm the sustainability of the $500 million buyback program given the increase in total debt to $585.9 million and the associated interest expense.
• HP Litigation Outcome: Monitor the appeal process regarding the HP patent infringement case, as a reversal of the non-infringement ruling could impact future earnings.
• SFAS 123(R) Impact: Assess the specific valuation method the company will use for stock options under the new standard, as this will materially reduce reported net income starting mid-2005.
• Inventory Levels: Review the $12.1 million increase in inventory, which management attributes to lower-than-expected sales, to ensure it does not signal future write-downs.